An interventional study of Inulin and Lifestyle intervention in Overweight and Obesity, sponsored by Max Planck Institute for Human Cognitive and Brain Sciences. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-29.
Sponsored by Max Planck Institute for Human Cognitive and Brain Sciences · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 338 studies in Obesity with a site in Germany — 75 open to participants now, 110 under way, 49 of them phase 3. Obesity · Germany.
Among the 338 studies in Obesity with a site in Germany, this one is the 185th largest by planned enrollment of the 276 interventional ones that give a count, is one of 14 that started in 2022, is one of 106 with no phase, reaches primary completion later than 6 of the 109 other live ones, and was the 200th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →75 of the 338 studies in Obesity with a site in Germany are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Germany, United States, Spain and 1 more country
Ages 45–65 · Women only
Boehringer Ingelheim · Sites in Germany, United States, Spain and 1 more country
Ages 18+
Eli Lilly and Company · Sites in Germany, United States, Argentina and 8 more countries
Ages 18+
German Diabetes Center · Sites in Germany
Ages 19–75
Technical University of Munich · Sites in Germany
Ages 18–60
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
338 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 27 · Phase 3 89 · Phase 4 12
First in 1998; this study’s year is marked. 14 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 160 across the 276 interventional studies, 165 across the 62 observational. Of the 198 that completed or were terminated, 32 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
174 of 338 have an industry lead sponsor. The 10 most frequent:
Max Planck Institute for Human Cognitive and Brain Sciences is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Max Planck Institute for Human Cognitive and Brain Sciences has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
38 of the studies in Obesity with a site in Germany that are under way reach primary completion within a year, 15 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
Add all 38 to your calendar (.ics) → With an account.
Among the 338 studies in Obesity with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators aim to test the hypothesis that a microbiome-changing dietary intervention improves food decision-making and to determine the underlying microbiotal and metabolic mechanisms. To this end, 90 overweight/obese adults will be enrolled in a randomized controlled trial to test the effects of a pre-biotic dietary intervention (supplementary intake of soluble fibre) or a behavioural lifestyle intervention (weekly educational program) vs. control condititon (supplementary intake of isocaloric starch) over a period of 26 weeks. Before and after the intervention/control period, participants will undergo task-based functional and structural MRI and cognitive testing. The gut microbiota will be assessed using 16S rDNA next-generation sequencing (V3/V4 region) in stool samples. Diet, anthropometry and lifestyle will be monitored with questionnaires and metabolomics will be assayed in peripheral blood and stool (e.g. SCFA). Using a modulation of gut-brain communication through a prebiotic diet and lifestyle intervention, respectively, the investigators will be able to discover microbiota communities that play a key role for eating behaviour. Related mechanistic insights could help to develop novel preventive and therapeutic options to combat unhealthy weight gain in our obesogenic society.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's planned enrollment of 90 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →Max Planck Institute for Human Cognitive and Brain Sciences is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
high-dose daily inulin
Dietary Supplement: Inulin
new educational program to change eating behaviour, provided through weekly sessions.
Behavioral: Lifestyle intervention
equicaloric daily maltodextrin
Dietary Supplement: Placebo
28g/day delivered in 2 sachets throughout the day with main meals
weekly educational sessions to improve individual's eating behaviour
equicaloric maltodextrin delivered in 2 sachets throughout the day with main meals
blood-oxygenation-level-dependent (BOLD) activity during food wanting
BOLD-acitvity will be measured using event-related echo-planar T2\*-weighted magnetic resonance imaging (MRI) during food wanting task according to previously described procedures (details of preprocessing at: https://osf.io/ynkxw). Onsets of food and art stimuli presentation will be modelled as separate regressors convolving delta functions with a canonical hemodynamic response function. Wanting rating scores (on an 8-point likert scale) per stimulus will be added as covariates. In a parallel model, kcal of food stimuli will be added multiplied with wanting scores to model high caloric food wanting interaction. At the group level, we will assess the contrasts food \> art and wanting modulation.
Time frame: 6 months
microbial alpha and beta diversity
Changes in alpha and beta diversity assessed using 16S rRNA sequencing of stool samples
Time frame: 6 months
fMRI BOLD activity memory performance
BOLD-acitvity will be measured using event-related echo-planar T2\*-weighted magnetic resonance imaging (MRI) during food wanting and food memory recognition tasks according to previously described procedures (details of preprocessing at: https://osf.io/ynkxw). Onsets of food and art stimuli presentation in encoding and recognition will be modelled as separate regressors convolving delta functions with a canonical hemodynamic response function. Correctly remembered and correctly rejected, as well as misses and false alarms will be modeled separately. In parallel models, similar and new items als well as wanting rating scores (on an 8-point likert scale) per stimulus and kcal of food stimuli multiplied with wanting scores will be added as covariates. At the group level, we will assess the contrasts correct \> false and wanting modulation.
Time frame: 6 months
satiety
self-reported hunger feeling on a 8-point score from minimum 0 (not at all) to maximum 8 (very much).
Time frame: 6 months
ghrelin
ghrelin pg/ml in blood
Time frame: 6 months
leptin
leptin ng/ml in blood
Time frame: 6 months
GLP-1
Glucagon-like peptide-1 (GLP-1) pg/ml in blood
Time frame: 6 months
PYY
peptide YY pg/ml in blood
Time frame: 6 months
insulin
insulin in blood uU/ml
Time frame: 6 months
HbA1c
hemoglycated globulin A1c in blood %
Time frame: 6 months
inflammatory markers
high sensitive C-reactive protein mg/l (and optionally tumor necrosis factor alpha and interleukin 6 in blood, pg/ml)
Time frame: 6 months
microbial metabolic markers in blood
short-chain fatty acids (SCFA), bile acids
Time frame: 6 months
body mass index
weight kg/height in m squared
Time frame: 6 months
waist hip ratio
waist (cm) to hip (cm) circumeference ratio
Time frame: 6 months
body fat
body fat % according to bioelectrical impedance analysis
Time frame: 6 months
food craving
assessed with the food craving questionnaire (Meule et al., 2012, German version).
Time frame: 6 months
executive attention performance
measured using the attention network task (ANT)
Time frame: 6 months
Plan to share: Yes — We plan to share all data openly but anonymized on secured German servers of the institute after registration with ID.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: after end of study for 5 years or longer
Access criteria: Registration on a website, providing copy of ID
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Dec 2024, 33 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 33 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Max Planck Institute for Human Cognitive and Brain Sciences